Stockreport

resTORbio Announces Initiation of Phase 3 Clinical Program of RTB101 in Clinically Symptomatic Respiratory Illness

RESTORBIO  (TORC) 
Last restorbio earnings: 3/12 07:30 am Check Earnings Report
PDF BOSTON, May 09, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), today announced the initiation of PROTECTOR 1, the first Phase 3 trial of RTB101, an orally ad [Read more]